HeartSciences Inc. (HSCS)
NASDAQ: HSCS · Real-Time Price · USD
2.190
-0.020 (-0.90%)
At close: Dec 18, 2025, 4:00 PM EST
2.230
+0.040 (1.83%)
After-hours: Dec 18, 2025, 6:07 PM EST
HeartSciences Revenue
HeartSciences had revenue of $2.42K in the quarter ending October 31, 2025. This brings the company's revenue in the last twelve months to $8.67K, down -41.03% year-over-year. In the fiscal year ending April 30, 2025, HeartSciences had annual revenue of $4.35K, down -76.61%.
Revenue (ttm)
$8.67K
Revenue Growth
-41.03%
P/S Ratio
799.23
Revenue / Employee
$578
Employees
15
Market Cap
6.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 4.35K | -14.25K | -76.61% |
| Apr 30, 2024 | 18.60K | 13.45K | 261.17% |
| Apr 30, 2023 | 5.15K | -9.22K | -64.17% |
| Apr 30, 2022 | 14.37K | -11.23K | -43.86% |
| Apr 30, 2021 | 25.60K | -38.58K | -60.11% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
HSCS News
- 3 days ago - HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 3 days ago - HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device - GlobeNewsWire
- 7 days ago - HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1 - GlobeNewsWire
- 3 months ago - HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results - GlobeNewsWire
- 4 months ago - HeartSciences Announces Conference Participation and Investor Webinar - GlobeNewsWire
- 5 months ago - HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results - GlobeNewsWire
- 7 months ago - HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis - GlobeNewsWire
- 7 months ago - Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value - GlobeNewsWire